Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Videos

Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC
Videos
Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC
01/26/2021
01/26/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
DPYD Genotyping Cost-Effective Screening Strategy Prior to Adjuvant Chemotherapy in Colon Cancer
Videos
DPYD Genotyping Cost-Effective Screening Strategy Prior to Adjuvant Chemotherapy in Colon Cancer
01/20/2021
01/20/2021
Journal of Clinical Pathways
Patients With Advanced HCC Often Do Not Receive Second-Line Therapy in Real-World Practice
Videos
Patients With Advanced HCC Often Do Not Receive Second-Line Therapy in Real-World Practice
01/19/2021
01/19/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
Videos
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
01/14/2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS,...
01/14/2021
Journal of Clinical Pathways
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice
Videos
Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice
01/14/2021
01/14/2021
Journal of Clinical Pathways
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
Videos
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
12/21/2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH,...
12/21/2020
Journal of Clinical Pathways
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways
JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Popular Articles

Conference Coverage
Use of Homologous Recombination Thresholds for Forecasting Response to Platinum-Based Treatment in Triple-Negative Breast Cancer
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an...
06/14/2022
Journal of Clinical Pathways
Shlomit Amar-Farkash, PhD, MSc
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...
Shlomit Amar-Farkash, PhD, MSc,...
07/14/2022
Journal of Clinical Pathways
News
Trends in Medicare Utilization and Reimbursement for Spinal Cord Stimulators
08/17/2022

Yvette C Terrie

Yvette C Terrie
The number of percutaneous and open procedures as well as reimbursement per procedure have progressively expanded from 2000 to 2019, according to a recent study.
The number of percutaneous and open procedures as well as reimbursement per procedure have progressively expanded from 2000 to 2019, according to a recent study.
The number of percutaneous and...
08/17/2022
Journal of Clinical Pathways
News
Score Model for Prediction and Prognosis of Patients With Advanced NSCLC Treated With Nivolumab or Pembrolizumab
09/27/2022

Yvette C Terrie

Yvette C Terrie
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways
Sayeh Lavasani, MD, MS, FRCPC
Videos
Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment
10/16/2022
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...
Sayeh Lavasani, MD, MS, FRCPC,...
10/16/2022
Journal of Clinical Pathways

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement